The type 2 diabetes market size in the 7 major markets was valued at USD 35 billion in 2023, driven by the rising prevalence of unhealthy lifestyle habits like obesity or excessive tobacco indulgence in these regions. The market is expected to grow at a CAGR of 8.4% during the forecast period of 2024-2032, with the values likely to rise from USD 37.9 billion in 2024 to USD 72.4 billion by 2032.
Type 2 diabetes is characterized by the body’s inability to produce insulin naturally leading to a rise in blood sugar levels in the body. High blood sugar levels can lead to major circulatory, immune, and nervous disorders. Symptoms include increased thirst, fatigue, frequent urination, blurred vision.
High fat distribution, weight, cholesterol levels and inactivity are one of the major causes fueling type 2 diabetes.
Emphasizing the serious complications of type 2 diabetes, which may lead to kidney disease, stroke, cardiac arrest and eye issues, the type 2 diabetes market demand has increased in recent years. Owing to the rising demand, prominent companies are stepping forward to expand their diabetes care portfolio. In March 2023, Sanofi announced their acquisition of Provention Bio, a United States based biopharmaceutical company in order to expand their diabetic care presence and lead market share.
The type 2 diabetes market value is likely to rise with continued research and development on bringing better drug with improved efficacy. The Lexington, a Massachusetts based biotech company is working towards developing a one-time gene therapy intended to lower body weight as well as blood sugar levels. The drug is set to mimic a human hormone called GLP-1 that is released in the gut in response to eating.
In April 2023, it was announced by Eli Lilly and Company that their Tirzepatide also known as Mounjaro led to 15.7% higher percentage of weight loss in their SURMOUNT-2 clinical trial program. It resulted in 81% to 97% of people reaching improved glucose control, which is significantly better than the competitors. This indicates that weigh loss drugs pose as a promising type 2 diabetes treatment method in upcoming years.
Market Breakup by Drug Class
Market Breakup by Application
Market Breakup by Distribution Channel
Market Breakup by Region
Diabetes is anticipated to affect approximately 1.3 billion people in the coming 30 years. High body mass index (BMI) has been declared as the primary reason for type 2 diabetes rates, accounting for 52.2% of the mortality. Therefore, weight loss and maintenance has been a key factor to prevent diabetes.
The United States has been dominating the type 2 diabetes market share owing to a well-established infrastructure and presence of influential healthcare companies, working seamlessly to provide novel solutions. In August 2023, the National Institutes of Health has offered USD 3.5 million to conduct a large-scale clinical trial testing that can be prove pivotal for new drug developments.
The Asia Pacific region, especially Japan, is projected to witness rapid growth in the forecast period. Having a considerable portion of the geriatric population can be considered as a major factor for type 2 diabetes market growth. To control and minimize the adverse effects of the disease, prominent organisations like WHO have been initiating significant campaigns. WHO has launched a new initiative called BeatDiabetes in the Indian region, aimed at increasing awareness and promoting a healthy lifestyle.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug Class||
|Breakup by Application||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Type 2 Diabetes Disease Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Type 2 Diabetes Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.3.2 France Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
5.4 Japan Type 2 Diabetes Disease Epidemiology Forecast (2017-2032)
6 Type 2 Diabetes Market Overview – 7MM
6.1 Type 2 Diabetes Market Historical Value (2017-2023)
6.2 Type 2 Diabetes Market Forecast Value (2024-2032)
7 Type 2 Diabetes Market Landscape – 7MM
7.1 Type 2 Diabetes: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Type 2 Diabetes: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Diagnosis Method
8 Type 2 Diabetes Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Type 2 Diabetes Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Type 2 Diabetes Market Segmentation – 7MM
11.1 Type 2 Diabetes Market by Drug Class
11.1.1 Market Overview
11.1.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
11.1.3 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
11.1.5 Alpha-glucosidase Inhibitors
11.1.7 Other Insulin Secretagogues
11.1.9 Sodium Glucose Cotransporter 2 Inhibitors
11.2 Type 2 Diabetes Market by Application
11.2.1 Market Overview
11.2.2 Glycemic Control
11.2.3 Cardiovascular Safety
11.2.4 Hypoglycemia Avoidance
11.3 Type 2 Diabetes Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online Pharmacies
11.4 Type 2 Diabetes Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
184.108.40.206 United Kingdom
12 United States Type 2 Diabetes Market
12.1 Type 2 Diabetes Market Historical Value (2017-2023)
12.2 Type 2 Diabetes Market Forecast Value (2024-2032)
12.3 Type 2 Diabetes Market by Type
12.4 Type 2 Diabetes Market by Treatment Type
13 EU-4 and United Kingdom Type 2 Diabetes Market
13.1 Type 2 Diabetes Market Historical Value (2017-2023)
13.2 Type 2 Diabetes Market Forecast Value (2024-2032)
13.3 Germany Type 2 Diabetes Market Overview
13.3.1 Type 2 Diabetes Market by Type
13.3.2 Type 2 Diabetes Market by Treatment Type
13.4 France Type 2 Diabetes Market Overview
13.4.1 Type 2 Diabetes Market by Type
13.4.2 Type 2 Diabetes Market by Treatment Type
13.5 Italy Type 2 Diabetes Market Overview
13.5.1 Type 2 Diabetes Market by Type
13.5.2 Type 2 Diabetes Market by Treatment Type
13.6 Spain Type 2 Diabetes Market Overview
13.6.1 Type 2 Diabetes Market by Type
13.6.2 Type 2 Diabetes Market by Treatment Type
13.7 United Kingdom Type 2 Diabetes Market Overview
13.7.1 Type 2 Diabetes Market by Type
13.7.2 Type 2 Diabetes Market by Treatment Type
14 Japan Type 2 Diabetes Market
14.1 Type 2 Diabetes Market Historical Value (2017-2023)
14.2 Type 2 Diabetes Market Forecast Value (2024-2032)
14.3 Type 2 Diabetes Market by Type
14.4 Type 2 Diabetes Market by Treatment Type
15 Middle East and Africa Type 2 Diabetes Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.5 South Africa
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Bayer AG
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.2 Amgen Inc.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.3 Boehringer Ingelheim International GmbH
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.4 Takeda Pharmaceutical Co. Ltd
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.5 GlaxoSmithKline Plc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.6 Eli Lilly and Co.
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.7 Chugai Pharmaceutical Co.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.8 Novo Nordisk
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.9 Merck & Co., Inc.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
20.11 Sanofi Aventis A/S
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisitions
20.12 Bristol-Myers Squibb
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisitions
20.13 Pfizer Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisitions
21 Type 2 Diabetes - Distribution Model (Additional Insight)
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 35 billion in 2023, driven by the increasing prevalence of alcohol, tobacco indulgence, and other harmful lifestyle patterns across the seven major markets.
The market is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, likely to reach a market value of USD 72.4 billion by 2032.
The market demand has increased with the lifestyle changes that entails a sedentary lifestyle and unhealthy dietary habits. This has increased the BMI (body mass index) and helped in rapid spread of type 2 diabetes in the major markets.
One time gene therapies are being developed to regulate weight as well as reduce the prevalence of type 2 diabetes. Drugs like Tirzepatide are under clinical trials to be used for weight loss.
The major regions of the market include United States, Japan, and EU-4 and the United Kingdom. EU-4 includes Germany, France, Italy, and Spain.
It includes Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, other insulin secretagogues, biguanides, and sodium glucose cotransporter 2 inhibitors.
Common application areas include glycemic control, cardiovascular safety, and hypoglycemia avoidance, among others.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Key players involved in the market are Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Co. Ltd, GlaxoSmithKline Plc., Eli Lilly and Co., Chugai Pharmaceutical Co., Novo Nordisk, Merck & Co., Inc., AstraZeneca, Sanofi Aventis A/S, Pfizer Inc., and Bristol-Myers Squibb.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.